BAJAJ FINSERV DIRECT LIMITED
IPO-Insights

Hindustan Laboratories IPO Updates

authour img
Anshika

Table of Contents

Learn about Hindustan Laboratories Limited’s Draft Red Herring Prospectus (DRHP) filing, business operations, financial context, and the proposed utilisation of funds as outlined in public disclosures.

Hindustan Laboratories Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) as part of its plan to raise capital through an initial public offering. The DRHP outlines the company’s pharmaceutical manufacturing operations, business strategy, financial performance, and the broad structure of the proposed public issue.

Hindustan Laboratories IPO Filing (DRHP)

The DRHP provides an overview of the proposed IPO and sets out the company’s financials, governance framework, and business outlook.

Filing Overview

Hindustan Laboratories Limited filed its Draft Red Herring Prospectus with SEBI in January 2026, marking the formal initiation of its IPO process. The filing is currently under regulatory review. Upon receipt of SEBI observations and subsequent approvals, the company is expected to file the Red Herring Prospectus (RHP), announce the price band, and disclose the IPO opening and closing dates.

The equity shares are proposed to be listed on recognised stock exchanges in India, subject to regulatory clearances.

Issue Structure

As per the DRHP, the proposed IPO is expected to comprise the following components:

Particulars Details

Issue Type

Fresh Issue of Equity Shares + Offer for Sale (OFS)

Face Value

₹10

Issue Size

1.41 Crore

Proposed Listing

NSE and BSE

Price Band

To be announced in RHP

Book Running Lead Managers

Choice Capital Advisors Pvt Ltd

Registrar to the Issue

MUFG Intime India Pvt Ltd

These details reflect indicative disclosures available at the DRHP stage and are subject to change based on SEBI observations and final approvals.

About the Company

Hindustan Laboratories Limited is a pharmaceutical company engaged in manufacturing and distribution of pharmaceutical formulations. The company produces a wide range of products including tablets, capsules, syrups, powders, and injectable formulations across multiple therapeutic categories.

Its operations are supported by manufacturing facilities equipped with modern pharmaceutical production technology, quality control systems, and regulatory compliance infrastructure. The company maintains relationships with distributors, retailers, and healthcare providers across India, enabling broad market reach and product distribution.

Hindustan Laboratories operates in India’s growing pharmaceutical sector, supported by increasing healthcare spending, rising demand for affordable medicines, and expansion of pharmaceutical consumption across population segments. Strategic investments in manufacturing capacity, product innovation, and distribution networks support its competitive positioning in the pharmaceutical manufacturing and distribution market.

IPO Objectives

According to the DRHP, the proceeds from the Fresh Issue are proposed to be utilised towards the following broad objectives:

Fund Allocation Purpose

Capital Expenditure

Expansion of manufacturing facilities, advanced pharmaceutical production equipment, formulation lines, quality testing laboratories, and manufacturing technology

Research & Development

Development of new pharmaceutical formulations, expansion into new therapeutic categories, product innovation, and regulatory approvals

Working Capital

Raw material procurement, inventory management, distributor network support, and operational expenses

Debt Repayment (if any)

Optimisation of capital structure and reduction in borrowing costs

General Corporate Purposes

Administrative flexibility and strategic initiatives

These objectives aim to enhance manufacturing capacity, expand the pharmaceutical product portfolio, and support long-term growth in India’s pharmaceutical sector.

Financial Highlights

The DRHP provides an overview of Hindustan Laboratories Limited’s financial performance over recent periods, offering insight into its operational scale.

Key Financial Metrics (as disclosed in DRHP)

Fiscal Year / Period Revenue (₹ crore) EBITDA (₹ crore) Profit After Tax (₹ crore)

FY24

186.36

44.09

34.13

FY25

219.74

53.87

41.26

H1 FY26

112.63

As per DRHP

18.20

*Detailed year-wise financial statements, including audited figures, are available in the DRHP and should be referred to for complete financial information.

Hindustan Laboratories IPO Timeline Summary

The table below summarises the current status of the IPO process based on publicly available information:

Milestone / Stage Date (or Status) Details

DRHP filed with SEBI

January 2026

Draft Red Herring Prospectus filed for regulatory review

SEBI observations

Awaited

Subject to regulatory review

SEBI approval

Awaited

Post DRHP review

Red Herring Prospectus (RHP)

To be announced

Post SEBI observations

IPO Opening Date

To be announced

Final dates to be declared

IPO Closing Date

To be announced

As per RHP

Allotment of Shares

To be announced

Post IPO closure

Listing on NSE/BSE

To be announced

Post allotment and listing formalities

Note: Investors should refer to official filings for final IPO dates to learn more about Hindustan Laboratories IPO listing details and price, and listing timelines.

Check other upcoming ipo’s here : Upcoming IPO

Disclaimer

This content is for informational purposes only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Sources

  • LiveMint — IPO News and Updates, https://www.livemint.com/market/ipo

  • Economic Times — IPO News: Latest IPO News, Upcoming IPO, https://economictimes.indiatimes.com/markets/ipo 

  • Financial Express — IPO News, https://www.financialexpress.com/market/ipo-news/ 

  • NDTV Profit — IPOs, https://www.ndtvprofit.com/ipos 

  • Business Today — IPO Corner: Latest IPO News & Analysis, https://www.businesstoday.in/markets/ipo-corner 

FAQs

When did Hindustan Laboratories Limited file its DRHP?

Hindustan Laboratories Limited filed its Draft Red Herring Prospectus with the Securities and Exchange Board of India on 3 January 2026, formally initiating the regulatory process for its proposed initial public offering in the Indian capital markets.

The Hindustan Laboratories Limited IPO remains at the Draft Red Herring Prospectus review stage, with observations and approvals from the Securities and Exchange Board of India awaited before proceeding to finalise the Red Herring Prospectus and subscription dates.

The Hindustan Laboratories Limited IPO comprises a fresh issue of up to 50 Lakh equity shares alongside an offer for sale of up to 91 Lakh equity shares by existing shareholders, with final allocation detailed in the Red Herring Prospectus.

The equity shares are proposed to be listed on National Stock Exchange and Bombay Stock Exchange, subject to regulatory approvals.

Hindustan Laboratories Limited proposes utilising fresh issue proceeds for funding working capital requirements, manufacturing expansion, research and development initiatives, potential debt repayment, and general corporate purposes to support operational growth.

View More
writer-img-alt
Hi! I’m Anshika
Financial Content Specialist
writer-img-alt

Anshika brings 7+ years of experience in stock market operations, project management, and investment banking processes. She has led cross-functional initiatives and managed the delivery of digital investment portals. Backed by industry certifications, she holds a strong foundation in financial operations. With deep expertise in capital markets, she connects strategy with execution, ensuring compliance to deliver impact. 

Home
Home
ONDC_BD_StealDeals
Steal Deals
Free CIBIL Score
CIBIL Score
Free Cibil
Explore
Explore
chatbot
Yara AI